Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details the exercise of nil-cost options and subsequent sales of shares to meet tax liabilities under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the Company. It exclusively reports on specific equity transactions by executives. The following transaction data is provided:
- Instrument: Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ADSs) (ISIN: US37733W1053).
- Transaction Dates: February 17, 2020, and February 18, 2020.
- Exercise Price: £0.00 (Nil-cost options).
- Sale Prices (GBP): Ranged from £16.614 to £16.714 per Ordinary Share.
- Sale Price (USD): $43.544 per ADS.
- Exchanges: London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
Material Changes
As this filing is a regulatory disclosure of specific executive transactions rather than a periodic financial report, there are no material changes in business operations, financial performance, or market conditions reported versus prior periods. The transactions represent standard vesting and tax-withholding events under existing compensation plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The transactions are routine exercises of deferred bonus awards and matching awards granted on February 15, 2017.
Important Facts for Investors to Verify
- Executive Participation: Transactions involved Ms. E. Walmsley (CEO), Mr. R. Connor (President, Global Vaccines), Mr. N. Hirons (SVP, Global Ethics and Compliance), Mr. B. McNamara (CEO, GSK Consumer Healthcare), Mr. D. Redfern (Chief Strategy Officer), and Mr. P. Thomson (President, Global Affairs).
- Net Retention: Executives exercised nil-cost options and immediately sold a portion of the shares to cover tax liabilities. The net effect is an increase in share ownership for the executives, though the exact net retained amount requires calculation based on the specific deferred and matching volumes listed.
- Market Pricing: The sale prices (approx. £16.60-£16.70 and $43.54) reflect the market value of GSK shares on the transaction dates.
- Plan Details: All transactions relate to the 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.